1 active not recruiting, 1 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Malignant Retroperitoneal Neoplasm: new trials by email Literature Review of Malignant Retroperitoneal Neoplasm trials Research Report on Malignant Retroperitoneal Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery Eribulin Mesylate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Liposarcoma, Malignant Abdominal Neoplasm | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 15 | 2018-03-19 | 2026-04-08 |
Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Liposarcoma (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1) · Uterine Cervical Neoplasms (1)
Neoplasms (2) · Abdominal Neoplasms (1) · Adnexal Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms by Histologic Type (1)
CTLA-4 Antigen (1) · Ipilimumab (1) · Nivolumab (1) · Pharmacogenomic Variants (1) · Radiotherapy, Intensity-Modulated (1) · eribulin (1)
M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1)
United States (2)
Amir A Jazaeri (1) · Lara E Davis (1)